Sphere Fluidics, a number one supplier of modern microfluidics-based options for single-cell evaluation and isolation, right now introduced the appointment of Dale Levitzke as CEO with quick impact, as Dr. Frank F. Craig, present CEO and co-founder, proclaims his retirement.
Dale joins Sphere Fluidics with over 25 years’ expertise within the life science instruments, biopharma, and biotechnology industries, the place he has constructed a robust monitor report in efficiently driving innovation, business progress, and IPO methods. In his position as CEO, Dale will form Sphere Fluidics’ future business enterprise and progress the Firm’s continued world enlargement technique to achieve new prospects and create worth for shareholders.
All through his profession, Dale has targeted on supporting early-stage and VC-backed pioneering instruments corporations and steering them in the direction of world market success. Earlier than becoming a member of Sphere Fluidics, he was Senior VP of World Gross sales and Assist at Vizgen and on this position established a worldwide business infrastructure and quickly scaled the Firm’s operations. Previous to this, as VP Worldwide Gross sales and Advertising and marketing at Dropworks Inc., Dale’s contributions have been instrumental in growing an built-in Digital Droplet PCR platform, and his strategic management culminated within the Firm’s acquisition by Bio-Rad for $125 million. He has additionally held key senior positions main business enlargement at NanoString Applied sciences, Illumina Inc., and Helixis Inc. Dale holds a BSc (Hons) in Molecular Biology and Genetics from La Trobe College in Melbourne, Australia.
Dr. Frank F. Craig co-founded Sphere Fluidics, alongside Professor Chris Abell and Professor Wilhelm Huck, earlier than changing into CEO in 2010. On this time, he has led the commercialization of novel merchandise and R&D providers that leverage the Firm’s proprietary picodroplet expertise, and uniquely established it inside the life science instruments trade to handle a rising portfolio of markets, together with biologics discovery, cell remedy and artificial biology. Sphere Fluidics has a confirmed monitor report of over 400 worldwide prospects, together with collaborations with seven of the world’s Prime 10 pharma corporations, over £40 million in funding (from prestigious angel and VC funds), and a portfolio of 135 worldwide patents. The Firm has been effectively positioned to drive this subsequent section of business growth ahead.
Sphere Fluidics’ picodroplet expertise and microfluidics platforms are reworking single cell evaluation and isolation capabilities, bringing new potentialities to biopharmaceutical analysis and growth. I’d wish to thank Frank for his dedication to rising an organization that prides itself on delivering high-quality services and products to its prospects. I stay up for becoming a member of the staff to proceed to steer and drive its formidable plans for business progress, worldwide enlargement, and eventual exit.”
Dale Levitzke, Incoming CEO, Sphere Fluidics
Dr. Frank F. Craig, departing CEO, Sphere Fluidics, commented: “It has been a privilege to function CEO of Sphere Fluidics for over 14 years and I’m delighted to go the baton onto Dale as he takes over as CEO. His expertise of driving innovation and business success shall be pivotal to advancing Sphere Fluidics’ formidable strategic imaginative and prescient and plans for business progress.”
